Cargando…
SARS-CoV-2 vaccine development, access, and equity
Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563686/ https://www.ncbi.nlm.nih.gov/pubmed/33064151 http://dx.doi.org/10.1084/jem.20201288 |
_version_ | 1783595543063166976 |
---|---|
author | Kim, Jerome H. |
author_facet | Kim, Jerome H. |
author_sort | Kim, Jerome H. |
collection | PubMed |
description | Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort—cooperation, commitment, time, and funding—to be effective. |
format | Online Article Text |
id | pubmed-7563686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75636862020-10-27 SARS-CoV-2 vaccine development, access, and equity Kim, Jerome H. J Exp Med Viewpoint Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort—cooperation, commitment, time, and funding—to be effective. Rockefeller University Press 2020-10-16 /pmc/articles/PMC7563686/ /pubmed/33064151 http://dx.doi.org/10.1084/jem.20201288 Text en © 2020 Kim http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Viewpoint Kim, Jerome H. SARS-CoV-2 vaccine development, access, and equity |
title | SARS-CoV-2 vaccine development, access, and equity |
title_full | SARS-CoV-2 vaccine development, access, and equity |
title_fullStr | SARS-CoV-2 vaccine development, access, and equity |
title_full_unstemmed | SARS-CoV-2 vaccine development, access, and equity |
title_short | SARS-CoV-2 vaccine development, access, and equity |
title_sort | sars-cov-2 vaccine development, access, and equity |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563686/ https://www.ncbi.nlm.nih.gov/pubmed/33064151 http://dx.doi.org/10.1084/jem.20201288 |
work_keys_str_mv | AT kimjeromeh sarscov2vaccinedevelopmentaccessandequity |